Table 3.

Drugs for each targeted pathway associated with osteosarcoma and their therapeutic targets.

Action Pathway	Drugs	Target of Action	References
DNA damage repair and cell cycle	AZD1775 Palbociclib Dinaciclib Alisertib AZD1152 HOI-07	WEE1 inhibitor CDK4/6 inhibitors multi-CDK inhibitors AURKA inhibitor AURKB inhibitor	[61] [65] [67] [69] [70] [70]
VEGF and PDGF	Sorafenib Cabozantinib Lenvatinib Regorafenib Anlotinib Sunitinib	VEGFR inhibitors VEGFR and PDGFR inhibitors	[66] [75] [76,77] [78] [88] [89]
IGF	R1507	IGF-1R inhibitor	[101]
PI3K/mTOR	Buparlisib Rapamycin Everolimus	PI3K inhibitor mTOR inhibitors	[109] [110] [109,111]
MYC	THZ1 JQ1	MYC super-enhancer inhibitors	[120] [121]